Cancer medicines
Daratumumab
Daratumumab
A CD38-targeting antibody for multiple myeloma.
Sources checked · Introductory guide
On this page
How it works
It binds CD38 and promotes cancer cell killing through several immune mechanisms.[3]
Where it is used
Used in selected newly diagnosed or relapsed/refractory myeloma. Distinguish the combination and intravenous versus subcutaneous formulations.[1]
Key safety points
Monitor administration reactions and infection. It can affect blood compatibility tests: confirm testing before treatment and disclose its use whenever transfusion is needed.[2]
Questions for your care team
- How should formulation, infection prevention and pretransfusion records be prepared?
Sources and scope
Source documents are in English.
Entries summarize and translate linked official public sources. The source-check date records when those sources were checked; it does not indicate a clinician’s review.
- NCI · Daratumumab (opens in a new tab)
- MedlinePlus · Daratumumab (opens in a new tab)
- NCI Drug Dictionary · Daratumumab (opens in a new tab)
General information based on official public sources. This is not a complete list of uses or side effects. Individual treatment decisions require your care team and current source documents. US-source uses do not establish local approval or reimbursement.